SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity. Part 1: Cellular pharmacology, in vitro and initial in vivo antitumor activity

Cancer Research

Volumn 64, Issue 18, 2004, Pages 6693-6699

  Hartley, John A ^a,b   Spanswick, Victoria J ^a   Brooks, Natalie ^a   Clingen, Peter H ^a   McHugh, Peter J ^a   Hochhauser, Daniel ^a   Pedley, R Barbara ^b   Kelland, Lloyd R ^c,f   Alley, Michael C ^d   Schultz, Robert ^d   Hollingshead, Melinda G ^d   Schweikart, Karen M ^d   Tomaszewski, Joseph E ^d   Sausville, Edward A ^d   Gregson, Stephen J ^e   Howard, Philip W ^e   Thurston, David E ^e  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d NATIONAL CANCER INSTITUTE   (United States)

^e IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^f ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,11A TETRAHYDRO 8 HYDROXY 7 METHOXY 5H PYRROLO[2,1 C][1,4]BENZODIAZEPIN 5 ONE; ANTINEOPLASTIC AGENT; CELL DNA; CHLORMETHINE; CISPLATIN; DIMER; DSB 120; NSC 694501; PURINE; PYRIMIDINE; PYRROLO[2,1 C][1,4]BENZODIAZEPINE DERIVATIVE; SJG 136; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CANCER INHIBITION; CANCER MODEL; CELL ASSAY; CELL DEATH; CELL KILLING; COLON TUMOR; COMET ASSAY; CONTROLLED STUDY; DNA CROSS LINKING; DNA DETERMINATION; DNA SEQUENCE; DNA STRUCTURE; DOSE RESPONSE; DRUG DESIGN; DRUG DNA BINDING; DRUG DNA INTERACTION; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; FEMALE; HOLLOW FIBER; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LC 50; MOLECULAR DYNAMICS; MOUSE; MOUSE STRAIN; NONHUMAN; OVARY TUMOR; PRIORITY JOURNAL; TUMOR CELL CULTURE; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZODIAZEPINES; BENZODIAZEPINONES; CELL LINE, TUMOR; COMET ASSAY; CROSS-LINKING REAGENTS; DNA; DOGS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MICE; MICE, NUDE; PYRROLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 4644353500     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-2941     Document Type: Article

References (41)

1. Thurston, DE. Advances in the study of pyrrolo[2,1-c][1,4]benzodiazepine (PBD) antitumour antibiotics. In: Neidle S, Waring MJ, editors. Topics in molecular and structural biology: molecular aspects of anticancer drug-DNA interactions. London: The Macmillan Press Ltd.; 1993. p. 54-88.
2. Puvvada MS, Forrow SA, Hartley JA, et al. Inhibition of bacteriophage T7 RNA polymerase in vitro transcription by DNA-binding pyrrolo[2,1-c][1,4] benzodiazepines. Biochemistry 1997;36:2478-84.
3. Hurley LH, Reck T, Thurston DE, et al. Pyrrolo[1,4]benzodiazepine antitumor antibiotics: relationship of DNA alkylation and sequence specificity to the biological activity of natural and synthetic compounds. Chem Res Toxicol 1988;1:258-68.
4. Thurston DE, Morris SJ, Hartley JA. Synthesis of a novel GC-specific covalent-binding DNA affinity-cleaving agent based on pyrrolobenzodiazepines. J Chem Soc Chem Commun 1996;563-5.
5. Wilson SC, Howard PW, Forrow SM, et al. Design, synthesis and evaluation of a novel sequence-selective epoxide-containing DNA cross-linking agent based on the pyrrolo[2,1-c][1,4]benzodiazepine system. J Med Chem 1999;42:4028-41.
6. Thurston DE, Bose DS, Thompson AS, et al. Synthesis of sequence-selective C8-linked pyrrolo[2,1-c][1,4]benzodiazepine DNA interstrand cross-linking agents. J Org Chem 1996;61:8141-7.
7. Bose DS, Thompson AS, Ching J, et al. Rational design of a highly efficient irreversible DNA interstrand cross-linking agent based on the pyrrolobenzodiazepine ring system. J Am Chem Society 1992;114:4939-41.
8. Bose DS, Thompson AS, Smellie M, et al. Effect of linker length on DNA-binding affinity, crosslinking efficiency and cytotoxicity of C8-linked pyrrolobenzodiazepine dimers. J Chem Soc Chem Commun 1992;14:1518-20.
9. Smellie M, Kelland LR, Thurston DE, Souhami RL, Hartley JA. Cellular pharmacology of novel C8-linked anthramycin-based sequence-selective DNA minor-groove cross-linking agents. Br J Cancer 1994;70:48-53.
10. Mountzouris JA, Wang J-J, Thurston DE, Hurley LH. Comparison of a DSB-120 DNA interstrand cross-linked adduct with the corresponding bis-tomaymycin adduct: an example of a successful template-directed approach to drug design based upon the monoalkylating compound tomaymycin. J Med Chem 1994;37:3132-40.
11. Jenkins TC, Hurley LH, Neidle S, Thurston DE. Structure of a covalent DNA minor groove adduct with a pyrrolobenzodiazepine dimer: evidence for sequence-specific interstrand cross-linking. J Med Chem 1994;37:4529-37.
12. Walton MI, Goddard P, Kelland LR, Thurston DE, Harrap KR. Preclinical pharmacology and antitumour activity of the novel sequence-selective DNA minor-groove cross-linking agent DSB-120. Cancer Chemother Pharm 1996;38:431-8.
13. Gregson SJ, Howard PW, Jenkins TC, Kelland LR, Thurston DE. Synthesis of a novel C2/C2′-exo unsaturated pyrrolobenzodiazepine crosslinking agent with remarkable DNA binding affinity and cytotoxicity. J Chem Soc Chem Commun 1999;9:797-8.
14. Morris SJ, Thurston DE, Nevell TG. Evaluation of the electrophilicity of DNA binding pyrrolo[2,1-c][1,4]benzodiazepines by HPLC. J Antibiot 1990;43:1286-92.
15. Gregson SJ, Howard PW, Hartley JA, et al. Design, synthesis and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient crosslinking ability and potent cytotoxicity. J Med Chem 2001;44:737-48.
16. Monks A, Scudiero D, Skehan P, et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst (Bethesda) 1991;83:757-66.
17. Monks A, Scudiero DA, Johnson GS, Paull KD, Sausville EA. The NCI anti-cancer drug screen: a smart screen to identify effectors of novel targets. Anticancer Drug Design 1997;12:533-41.
18. Paull KD, Shoemaker RH, Hodes L, et al. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst (Bethesda) 1989;81:1088-92.
19. Sausville EA, Johnson JI. Molecules for the millennium: how will they look? New drug discovery in the year 2000. Br J Cancer 2000;83:1401-4.
20. Alley MC, Pacula-Cox CM, Hursey ML, Rubinstein LR, Boyd MR. Morphometric and colorimetric analyses of human tumor cell line growth and drug sensitivity in soft agar culture. Cancer Res 1991;51:1247-56.
21. Parchment RE, Volpe DA, LoRusso PM, Erickson-Miller CL, Murphy MJ Jr, Grieshaber CK. In vivo-in vitro correlation of myelotoxicity of 9-methoxypyrazoloacridine (NSC-366140, PD115934) to myeloid and erythroid hematopoietic progenitors from human, murine, and canine marrow. J Natl Cancer Inst (Bethesda) 1994;86:273-80.
22. Erickson-Miller CL, May RD, Tomaszewski JE, et al. Differential toxicity of camptothecin, topotecan, and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro. Cancer Chemother Pharmacol 1997;39:467-72.
23. Volpe DA, Tomaszewski JE, Parchment RE, et al. Myelotoxic effects of the bifunctional alkylating agent bizelesin to human, canine and murine myeloid progenitor cells. Cancer Chemother Pharmacol 1996;39:143-9.
24. Hollingshead MG, Alley MC, Camalier RF, et al. In vivo cultivation of tumor cells in hollow fibers. Life Sci 1995;57(2):131-41.
25. Hollingshead MG, Plowman J, Alley MC, Mayo JG, Sausville, EA The hollow fiber assay. In: Fiebig HH, Burger AM, editors. Relevance of tumor models for anticancer drug development: contributions in oncology, Vol. 54. Basel, Switzerland: Karger; 1999. p. 109-20.
26. Hartley JM, Spanswick VJ, Gander M, et al. Measurement of DNA crosslinking in patients on ifosfamide therapy using the single cell gel electrophoresis (comet) assay. Clin Cancer Res 1999;5:507-12.
27. Spanswick VJ, Hartley JM, Ward TH, Hartley JA. Measurement of drug-induced DNA interstrand crosslinking using the single cell gel electrophoresis (comet) assay. In: Brown R, Boger-Brown U, editors. Methods in molecular medicine. Cytotoxic drug resistance mechanisms, Vol. 28. New York: Humana Press; 1999. p. 143-54.
28. Olive PL, Banath JP, Durand RE. Heterogeneity in radiation-induced DNA damage and repair in tumor and normal cells measured using the "comet" assay. Rad Res 1990;122:86-94.
29. Jones M, Siracky J, Kelland LR, Harrap KR. Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenografts. Br J Cancer 1993;67:24-9.
30. Webley SD, Francis R, Pedley B, et al. Measurement of the critical DNA lesions produced by antibody directed enzyme prodrug therapy (ADEPT) in vitro, in vivo and in clinical material. Br J Cancer 2001;84:1671-6.
31. Ding ZM, Hurley LH. DNA interstrand crosslinking, DNA sequence specificity, and induced conformational changes produced by a dimeric analog of (+)-CC-1065. Anticancer Drug Design 1991;6:427-52.
32. Pitot HC, Reid JM, Sloan JA, et al. A phase I study of bizelesin (NSC 615291) in patients with advanced solid tumors. Clin Cancer Res 2002;8:712-7.
33. Schwartz GH, Patnaik A, Hammond LA, et al. A phase I study of bizelesin. a highly potent and selective DNA-interactive agent, in patients with advanced solid malignancies. Ann Oncol 2003;14:775-82.
34. De Silva IU, McHugh PJ, Clingen PH, Hartley JA. Defining the roles of nucleotide excision repair and recombination in the repair of interstrand crosslinks in mammalian cells. Mol Cell Biol 2000;20:7980-90.
35. McHugh PJ, Spanswick VJ, Hartley JA. Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance. Lancet Oncol 2001;2:483-90.
36. Clingen PH, De Silva IU, Ghadessy FJ, Thurston DE, Hartley JA. The role of nucleotide excision repair and homologous recombination in the sensitivity of mammalian cells to the minor groove crosslinking pyrrolo[2,1-c][1,4] benzodiazepine dimmer SJG-136 (NSC694501). Proc Am Assoc Cancer Res 2003;44:610.
37. Spanswick VJ, Craddock C, Sekhar M, et al. Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma. Blood 2002;100:224-9.
38. 2 block induced by DNA crosslinking agents and its possible consequences. Biochem Pharmacol 1988;37:2303-9.
39. Alley MC, Hollingshead MG, Pacula-Cox CM, et al. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent witih potent and broad spectrum antitumor activity. Part 2: efficacy evaluations. Cancer Res 2004;64:6700-6.
40. Hartley JA, Brooks N, McHugh PJ, et al. SJG-136 (NSC-D694501): a novel DNA sequence specific minor groove crosslinking agent with significant antitumor activity. Proc Am Assoc Cancer Res 2000;41:425.
41. Hartley JA, Spanswick VJ, Pedley B, et al. In vitro antitumor activity and in vivo DNA interstrand crosslinking by the novel pyrrolobenzodiazepine dimer SJG-136 (NSC 694501). Proc Am Assoc Cancer Res 2002;43:489.